Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
13. Mai 2021 09:15 ET
|
Vallon Pharmaceuticals Inc.
- Company remains on track to report pivotal data from lead program, ADAIR, in second half 2021 - Novel abuse-deterrent platform technology enables pipeline expansion opportunities across multiple...
Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum
26. April 2021 09:05 ET
|
Vallon Pharmaceuticals Inc.
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on April 29th at 10:30 AM ET PHILADELPHIA, PA, April 26, 2021 (GLOBE NEWSWIRE) -- Vallon...
Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
23. Februar 2021 09:05 ET
|
Vallon Pharmaceuticals Inc.
- Accomplished executive leader with more than 30 years of experience in finance and operations PHILADELPHIA, PA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON),...
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
12. Februar 2021 15:30 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting
08. Januar 2021 09:00 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc., (“Vallon” or the “Company”), a biopharmaceutical company focused on the development of novel drugs for CNS disorders,...
Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR
09. November 2020 09:00 ET
|
Vallon Pharmaceuticals Inc.
Results demonstrated that ADAIR had slower absorption and lower early exposure, and was less desirable to recreational drug abusers on key measures of abuse liability compared to commercially...